Ruth Duncan

Summary

Affiliation: Cardiff University
Country: UK

Publications

  1. ncbi request reprint Dendrimer biocompatibility and toxicity
    Ruth Duncan
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3XF, UK
    Adv Drug Deliv Rev 57:2215-37. 2005
  2. ncbi request reprint Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic
    R Duncan
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, Wales, UK
    J Control Release 74:135-46. 2001
  3. ncbi request reprint Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer
    R Duncan
    Centre for Polymer Therapeutics, Cardiff University, Cardiff, UK
    Endocr Relat Cancer 12:S189-99. 2005
  4. ncbi request reprint Polymer conjugates for drug targeting. From inspired to inspiration!
    Ruth Duncan
    Welsh School of Pharmacy, Centre for Polymer Therapeutics, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, UK
    J Drug Target 14:333-5. 2006
  5. doi request reprint Polymer masked-unmasked protein therapy. 1. Bioresponsive dextrin-trypsin and -melanocyte stimulating hormone conjugates designed for alpha-amylase activation
    Ruth Duncan
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3XF, UK
    Biomacromolecules 9:1146-54. 2008
  6. ncbi request reprint Polymer conjugates as anticancer nanomedicines
    Ruth Duncan
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3XF, UK
    Nat Rev Cancer 6:688-701. 2006
  7. ncbi request reprint Polymer therapeutics--polymers as drugs, drug and protein conjugates and gene delivery systems: past, present and future opportunities
    Ruth Duncan
    Welsh School of Pharmacy, Centre for Polymer Therapeutics, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK
    J Drug Target 14:337-41. 2006
  8. ncbi request reprint Designing polymer conjugates as lysosomotropic nanomedicines
    R Duncan
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3XF, Wales, UK
    Biochem Soc Trans 35:56-60. 2007
  9. doi request reprint Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt
    Ruth Duncan
    School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, UK
    Adv Drug Deliv Rev 61:1131-48. 2009
  10. ncbi request reprint The dawning era of polymer therapeutics
    Ruth Duncan
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, UK
    Nat Rev Drug Discov 2:347-60. 2003

Collaborators

Detail Information

Publications54

  1. ncbi request reprint Dendrimer biocompatibility and toxicity
    Ruth Duncan
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3XF, UK
    Adv Drug Deliv Rev 57:2215-37. 2005
    ....
  2. ncbi request reprint Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic
    R Duncan
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, Wales, UK
    J Control Release 74:135-46. 2001
    ..Moreover, bioresponsive polymer-based constructs able to promote endosomal escape and thus intracytoplasmic delivery of macromolecular drugs (peptides, proteins and oligonucleotides) are also under study...
  3. ncbi request reprint Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer
    R Duncan
    Centre for Polymer Therapeutics, Cardiff University, Cardiff, UK
    Endocr Relat Cancer 12:S189-99. 2005
    ....
  4. ncbi request reprint Polymer conjugates for drug targeting. From inspired to inspiration!
    Ruth Duncan
    Welsh School of Pharmacy, Centre for Polymer Therapeutics, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, UK
    J Drug Target 14:333-5. 2006
  5. doi request reprint Polymer masked-unmasked protein therapy. 1. Bioresponsive dextrin-trypsin and -melanocyte stimulating hormone conjugates designed for alpha-amylase activation
    Ruth Duncan
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3XF, UK
    Biomacromolecules 9:1146-54. 2008
    ..The choice of masking polymer, activation mechanism, and the rate of unmasking can be tailored to therapeutic application...
  6. ncbi request reprint Polymer conjugates as anticancer nanomedicines
    Ruth Duncan
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3XF, UK
    Nat Rev Cancer 6:688-701. 2006
    ..There is growing optimism that ever more sophisticated polymer-based vectors will be a significant addition to the armoury currently used for cancer therapy...
  7. ncbi request reprint Polymer therapeutics--polymers as drugs, drug and protein conjugates and gene delivery systems: past, present and future opportunities
    Ruth Duncan
    Welsh School of Pharmacy, Centre for Polymer Therapeutics, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK
    J Drug Target 14:337-41. 2006
  8. ncbi request reprint Designing polymer conjugates as lysosomotropic nanomedicines
    R Duncan
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3XF, Wales, UK
    Biochem Soc Trans 35:56-60. 2007
    ..The present paper reviews the clinical status of polymeric anticancer agents, the rationale for the design of polymer therapeutics and discusses the benefits and challenges of lysosomotropic delivery...
  9. doi request reprint Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt
    Ruth Duncan
    School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, UK
    Adv Drug Deliv Rev 61:1131-48. 2009
    ..The preclinical and clinical observations made in these, and clinical studies with other polymer conjugates, should shape the development of next generation anticancer polymer therapeutics...
  10. ncbi request reprint The dawning era of polymer therapeutics
    Ruth Duncan
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, UK
    Nat Rev Drug Discov 2:347-60. 2003
    ....
  11. ncbi request reprint Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 melanoma cells
    F Philipp Seib
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, King Edward VII Avenue, Cardiff University, Cardiff CF10 3XF, UK
    J Control Release 117:291-300. 2007
    ..A perception of the rate and mechanisms of cellular uptake of these vectors will be important in the context of their proposed use as drug delivery systems...
  12. ncbi request reprint Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells
    Francesca Greco
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Redwood Building, Cardiff University, King Edward VII Ave, Cardiff CF10 3XF, UK
    J Control Release 117:28-39. 2007
    ....
  13. doi request reprint Poly(amidoamine) conjugates containing doxorubicin bound via an acid-sensitive linker
    Nathalie Lavignac
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Redwood Building, Cardiff University, Cardiff, UK
    Macromol Biosci 9:480-7. 2009
    ..These results suggest that ISA23Dox is able to release biologically active Dox in vitro and that this conjugate might be suitable for further development...
  14. ncbi request reprint Establishment of subcellular fractionation techniques to monitor the intracellular fate of polymer therapeutics II. Identification of endosomal and lysosomal compartments in HepG2 cells combining single-step subcellular fractionation with fluorescent imag
    Maria Manunta
    Welsh School of Pharmacy, Centre for Polymer Therapeutics, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3XF, UK
    J Drug Target 15:37-50. 2007
    ....
  15. ncbi request reprint Studies on the mechanism of interaction of a bioresponsive endosomolytic polyamidoamine with interfaces. 1. Micelles as model surfaces
    Peter C Griffiths
    School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U K
    Biomacromolecules 8:1004-12. 2007
    ..5...
  16. ncbi request reprint Polymer therapeutics designed for a combination therapy of hormone-dependent cancer
    Maria J Vicent
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Redwood Building, CF10 3XF Cardiff, UK
    Angew Chem Int Ed Engl 44:4061-6. 2005
  17. doi request reprint The use of fluorescence microscopy to define polymer localisation to the late endocytic compartments in cells that are targets for drug delivery
    Simon C W Richardson
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Av, Cardiff, Wales CF10 3XF, UK
    J Control Release 127:1-11. 2008
    ..The technique described here is a particularly powerful tool as it circumvents fixation artefacts ensuring the retention of water-soluble polymers within the vesicles they occupy...
  18. ncbi request reprint Synthesis and preliminary evaluation of poly(amidoamine)-melittin conjugates as endosomolytic polymers and/or potential anticancer therapeutics
    Nathalie Lavignac
    Centre for Polymer Therapeutics, Welsh, School of Pharmacy Redwood Building, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, UK
    Int J Pharm 300:102-12. 2005
    ..However, this conjugate could have potential as a novel polymeric anticancer conjugate due to its lack of haemolytic activity at pH 7.4 and retention of cytotoxicity...
  19. doi request reprint Bioresponsive dextrin-rhEGF conjugates: in vitro evaluation in models relevant to its proposed use as a treatment for chronic wounds
    Joseph Hardwicke
    Wound Biology Group, Cardiff Institute of Tissue Engineering and Repair, Tissue Engineering and Reparative Dentistry, School of Dentistry, Cardiff University, Heath Park, Cardiff CF14 4XY, UK
    Mol Pharm 7:699-707. 2010
    ..These results suggest further preclinical in vivo evaluation of dextrin-rhEGF is warranted to determine whether conjugate pharmacokinetics and rhEGF liberation into such a complex and aggressive environment can still lead to bioactivity...
  20. ncbi request reprint Synthesis and endosomolytic properties of poly(amidoamine) block copolymers
    Nathalie Lavignac
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Redwood Building, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3XF, UK
    Macromol Biosci 4:922-9. 2004
    ..It would be interesting to study the body distribution of B2 and determine whether this toxin-delivering PAA is able to escape liver capture...
  21. doi request reprint Studies on the mechanism of action of dextrin-phospholipase A2 and its suitability for use in combination therapy
    Elaine L Ferguson
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3XF, UK
    Mol Pharm 7:510-21. 2010
    ..However, the enhanced cytotoxicity seen in the presence of doxorubicin suggested potential for development of a dextrin-PLA2/doxorubicin combination therapy...
  22. ncbi request reprint Polymer conjugates: nanosized medicines for treating cancer
    Maria J Vicent
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, UK
    Trends Biotechnol 24:39-47. 2006
    ..g. modulators of the cell cycle, signal transduction inhibitors and antiangiogenic drugs) in addition to polymer-drug combinations (e.g. endocrine- and chemo-therapy)...
  23. ncbi request reprint HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines
    Francesca Greco
    Welsh School of Pharmacy, Redwood Building, Cardiff University, Tenovus Centre for Cancer Research, King Edward VII Avenue, UK
    J Drug Target 13:459-70. 2005
    ....
  24. doi request reprint Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair
    Joseph Hardwicke
    Wound Biology Group, Cardiff Institute of Tissue Engineering and Repair, Tissue Engineering and Reparative Dentistry, School of Dentistry, Heath Park Campus, Cardiff University, Cardiff, UK
    J Control Release 130:275-83. 2008
    ..These observations suggest that this dextrin-rhEGF, and other dextrin-growth factor conjugates have potential for further development as bioresponsive nanomedicines for tissue repair...
  25. ncbi request reprint Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates
    Alison Paul
    School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, United Kingdom
    Biomacromolecules 8:1573-9. 2007
    ..5 nm) compared to FCE28068. In conclusion, we have shown that SANS will be a valuable tool to elucidate conformation-performance relationships for polymer-drug conjugates...
  26. doi request reprint Interaction of an endosomolytic polyamidoamine ISA23 with vesicles mimicking intracellular membranes: A SANS/EPR study
    Peter C Griffiths
    School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, UK
    Macromol Biosci 10:963-73. 2010
    ..The vesicle-mimetic models used here provide a new and useful tool for studying endosomolytic polymer/membrane interactions...
  27. ncbi request reprint HPMA copolymer-1,5-diazaanthraquinone conjugates as novel anticancer therapeutics
    Maria J Vicent
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, Cardiff, UK
    J Drug Target 12:503-15. 2004
    ..Nonetheless, the observed lysosomal activation of the HPMA copolymer-GFLG-amino-DAQ conjugates, suggests that evaluation of the antitumour potential in vivo is warranted...
  28. doi request reprint The effect of dextrin-rhEGF on the healing of full-thickness, excisional wounds in the (db/db) diabetic mouse
    Joseph T Hardwicke
    Wound Biology Group, Cardiff Institute of Tissue Engineering and Repair CITER, Tissue Engineering and Reparative Dentistry, School of Dentistry, Cardiff University, Heath Park, UK
    J Control Release 152:411-7. 2011
    ..05), relative to untreated, succinoylated dextrin and rhEGF alone controls. Overall, these findings support the further development of bioresponsive polymer conjugates, for tissue repair...
  29. doi request reprint Dextrin-phospholipase A2: synthesis and evaluation as a bioresponsive anticancer conjugate
    Elaine L Ferguson
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, United Kingdom
    Biomacromolecules 10:1358-64. 2009
    ..The reduced toxicity and alpha-amylase triggered activity of the dextrin-PLA(2) conjugate confirmed the potential of this approach for further development as a novel anticancer treatment...
  30. ncbi request reprint Characterising the size and shape of polyamidoamines in solution as a function of pH using neutron scattering and pulsed-gradient spin-echo NMR
    Zeena Khayat
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, King Edward s VII Avenue, Cardiff CF10 3XF, UK
    Int J Pharm 317:175-86. 2006
    ....
  31. ncbi request reprint Polyacetal-diethylstilboestrol: a polymeric drug designed for pH-triggered activation
    Maria J Vicent
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, University of Wales, Cardiff, UK
    J Drug Target 12:491-501. 2004
    ..Their in vitro characteristics suggest further in vivo evaluation is warranted...
  32. ncbi request reprint Establishment of subcellular fractionation techniques to monitor the intracellular fate of polymer therapeutics I. Differential centrifugation fractionation B16F10 cells and use to study the intracellular fate of HPMA copolymer - doxorubicin
    F Philipp Seib
    Welsh School of Pharmacy, Centre for Polymer Therapeutics, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, UK
    J Drug Target 14:375-90. 2006
    ..In conclusion, the B16F10 subcellular fractionation method developed here provides a useful tool to allow comparison of the intracellular trafficking of other polymer conjugates...
  33. doi request reprint Polymer coiled-coil conjugates: potential for development as a new class of therapeutic "molecular switch"
    Samuel P E Deacon
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, United Kingdom
    Biomacromolecules 12:19-27. 2011
    ..Observation that heterodimerization was achieved and that the polymer did not sterically disadvantage hybridization suggests an important future for this new family of polymer therapeutics...
  34. ncbi request reprint Polymer-protein and polymer-drug conjugates in cancer therapy
    Maya Thanou
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3XF, UK
    Curr Opin Investig Drugs 4:701-9. 2003
    ..Eleven polymer-drug conjugates have entered clinical development and activity has already been observed in chemotherapy refractory patients. Certain compounds have also demonstrated a marked reduction in drug toxicity...
  35. ncbi request reprint Understanding endocytic pathways and intracellular trafficking: a prerequisite for effective design of advanced drug delivery systems
    Arwyn T Jones
    Center for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, South Wales CF10 3XF, UK
    Adv Drug Deliv Rev 55:1353-7. 2003
  36. ncbi request reprint N-(2-hydroxypropyl)methacrylamide copolymer-6-(3-aminopropyl)-ellipticine conjugates. Synthesis, in vitro, and preliminary in vivo evaluation
    F Searle
    Centre for Polymer Therapeutics, School of Pharmacy, University of London, 29/39 Brunswick Square, London WC1N 1AX, UK
    Bioconjug Chem 12:711-8. 2001
    ..p. was somewhat more active (highest T/C value of 143%) than free APE (1 mg/kg) (T/C =127%). HPMA copolymer-APE conjugates warrant further evaluation as potential anticancer agents...
  37. doi request reprint Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities
    Ruth Duncan
    School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, UK
    Adv Drug Deliv Rev 62:272-82. 2010
    ....
  38. ncbi request reprint Hiroshi Maeda--defining the pathway to targeted cancer therapy
    Ruth Duncan
    Centre for Polymer Therapeutics Welsh School of Pharmacy Cardiff University, Cardiff, UK
    J Drug Target 15:456. 2007
  39. ncbi request reprint Dextrins as potential carriers for drug targeting: tailored rates of dextrin degradation by introduction of pendant groups
    D Hreczuk-Hirst
    Centre for Polymer Therapeutics, The School of Pharmacy, University of London, 29-39 Brunswick Square, London WC1N 1AX, UK
    Int J Pharm 230:57-66. 2001
    ....
  40. ncbi request reprint Poly(amidoamine) salt form: effect on pH-dependent membrane activity and polymer conformation in solution
    Ka Wai Wan
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, King Edward VII Avenue, Cardiff CF10 3XF, United Kingdom
    Biomacromolecules 5:1102-9. 2004
    ..This study clearly demonstrates the importance of optimization of the counterion form when developing endosomolytic polymers designed to mediate pH-dependent membrane permeabilization...
  41. ncbi request reprint HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation
    Elisabetta Gianasi
    Centre for Polymer Therapeutics, The School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    J Drug Target 10:549-56. 2002
    ..After i.v. administration, the platinum accumulation in B16F10 tumour tissue showed a 19-fold increase in Pt AUC for the malonate conjugate when compared to cisplatin administered equi-dose at its maximum tolerated dose (MTD) (1 mg/kg)...
  42. ncbi request reprint Understanding the mechanism of action of poly(amidoamine)s as endosomolytic polymers: correlation of physicochemical and biological properties
    P C Griffiths
    School of Chemistry, Cardiff University, PO Box 912, Cardiff CF10 3TB, United Kingdom
    Biomacromolecules 5:1422-7. 2004
    ..The results do, however, suggest that the charge on the polymer shows a closer correlation with the haemolysis activity rather than the polymer conformation...
  43. pmc PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination
    R Satchi
    Centre for Polymer Therapeutics, The School of Pharmacy, University of London, 29 39 Brunswick Square, London WCIN IAX, UK
    Br J Cancer 85:1070-6. 2001
    ..This study proves the concept of PDEPT and further optimisation is warranted...
  44. ncbi request reprint Poly(amidoamine)-mediated intracytoplasmic delivery of ricin A-chain and gelonin
    N G Pattrick
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, CF10 3XF, Cardiff, UK
    J Control Release 77:225-32. 2001
    ..26 mg/ml, respectively. In contrast, the neutral polymer dextran and the PAA ISA 22 were unable to mediate this effect. These observations suggest that specific PAA-toxin combinations warrant further development as novel therapeutics...
  45. ncbi request reprint Poly(amidoamine)s as potential nonviral vectors: ability to form interpolyelectrolyte complexes and to mediate transfection in vitro
    S C Richardson
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF
    Biomacromolecules 2:1023-8. 2001
    ..These properties suggest that PAAs warrant further development as endosomolytic vectors...
  46. ncbi request reprint Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates
    Lars Andersson
    PolyPeptide Laboratories Sweden AB, PO Box 30089, SE 20061 Limhamn, Sweden
    Biomacromolecules 6:914-26. 2005
    ..However, the successful scale-up synthesis of DBM2-PEG4000-S-PEG3000 constructs suggest that they are worthy of further investigation as carriers for controlled release and targeting of less hydrophobic agents...
  47. ncbi request reprint Novel monodisperse PEG-dendrons as new tools for targeted drug delivery: synthesis, characterization and cellular uptake
    Manuela Berna
    Department of Pharmaceutical Science, University of Padua, Via Marzolo 5, 35100 Padua, Italy
    Biomacromolecules 7:146-53. 2006
    ..These well-defined novel architectures have potential for further development as targetable drug delivery systems or tools for construction of structurally defined modified surfaces...
  48. ncbi request reprint PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity
    Francesco M Veronese
    Department of Pharmaceutical Science, University of Padua, Via F Marzolo 5, 35100 Padua, Italy
    Bioconjug Chem 16:775-84. 2005
    ..Further studies are warranted with PEG5000(L)-GFLG-Dox to determine its spectrum of antitumor activity and also the optimum dosing schedule before clinical testing...
  49. ncbi request reprint Polyacetal-doxorubicin conjugates designed for pH-dependent degradation
    Ryan Tomlinson
    Biomedical Polymers Group, Department of Pharmaceutics, The School of Pharmacy, University of London, UK
    Bioconjug Chem 14:1096-106. 2003
    ..2 wt % DOX content. Moreover, APEG-DOX exhibited lower uptake by liver and spleen. These observations suggest that APEG anticancer conjugates warrant further development as novel polymer therapeutics for improved tumor targeting...
  50. doi request reprint Effect of PEG molecular weight and linking chemistry on the biological activity and thermal stability of PEGylated trypsin
    Benjaporn Treetharnmathurot
    Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hatyai, Songkhla 90112, Thailand
    Int J Pharm 357:252-9. 2008
    ..PEG-trypsin conjugates containing the higher molecular weight of mPEG (5000 g/mol) were more stable than free trypsin, and the conjugate containing CC-mPEG 5000 g/mol had the best thermal stability...
  51. ncbi request reprint Total synthesis and preliminary biological evaluation of cis-solamin isomers
    Alex R L Cecil
    Department of Chemistry, The University of Southampton, Highfield, UK
    J Org Chem 69:3368-74. 2004
    ..The methodology was also applied to the synthesis of three further cis-solamin isomers 2, ent-1, and ent-2. Cytotoxicity and hemolytic properties of cis-solamin isomers and synthetic intermediates are reported...
  52. ncbi request reprint Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation
    Sunil Shaunak
    Faculty of Medicine, Imperial College London, Hammersmith Hospital, DuCane Road, London, W12 0NN, UK
    Nat Biotechnol 22:977-84. 2004
    ....
  53. pmc LEAPT: lectin-directed enzyme-activated prodrug therapy
    Mark A Robinson
    Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Mansfield Road, Oxford OX1 3TA, United Kingdom
    Proc Natl Acad Sci U S A 101:14527-32. 2004
    ....
  54. ncbi request reprint PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination
    Ronit Satchi-Fainaro
    Department of Cell Research and Immunology, Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
    Bioconjug Chem 14:797-804. 2003
    ..The PDEPT combination displayed no toxicity at the doses used, so further evaluation of this approach to establish the maximum tolerated dose (MTD) is recommended...